enGene Therapeutics Inc. (ENGN) Debt Components
- 2026-07-31: Notes Payable, CurrentUSD $199.00K.
- 2026-04-30: Notes Payable, CurrentUSD $193.00K.
- 2026-01-31: Notes Payable, CurrentUSD $188.00K.
- 2025-10-31: Notes Payable, CurrentUSD $8.00M.
enGene Therapeutics Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Notes Payable, Current USD |
|---|---|
| 2026-07-31 | $199.00K |
| 2026-04-30 | $193.00K |
| 2026-01-31 | $188.00K |
| 2025-10-31 | $8.00M |
| 2025-07-31 | $5.41M |
| 2025-04-30 | $3.57M |
| 2025-01-31 | $1.69M |
| 2024-10-31 | $699.00K |
| 2024-07-31 | $1.34M |
| 2023-10-31 | $562.00K |
| 2022-10-31 | $1.26M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |